Pepscan Therapeutics, a developer of protein mimicry technologies based in The Netherlands, has entered into a multi-target research agreement with an undisclosed U.S.-based antibody discovery company.
Pepscan will use its CLIPS (Chemical LInkage of Peptides onto Scaffolds ) platform and other protein mimicry technologies to work with the partner in the discovery of novel antibodies. Pepscan will receive R&D funding and could receive payments on the achievement of research and clinical milestones, as well as royalties on sales of products resulting from the collaboration. Financial details of the agreement were not disclosed.
"We are excited to collaborate in this partnership, since we strongly believe that Pepscan's peptide design and protein mimicry technology combined with our partner’s world-class platform for antibody discovery and optimization will yield truly innovative therapeutic products," said Wim Mol, CEO of Pepscan. "We recognize the perfect match of our combined technologies—Pepscan designing and providing tailored peptide immunogens, and our partner applying its state-of-the-art antibody discovery platform. We therefore believe that this agreement only forms the start of a promising and productive relationship between our two companies.”